Literature DB >> 27502451

Subclinical Mood and Cognition Impairments and Blood Pressure Control in a Large Cohort of Elderly Hypertensives.

Karolina Piotrowicz1, Aleksander Prejbisz2, Marek Klocek3, Roman Topór-Mądry4, Paulina Szczepaniak5, Kalina Kawecka-Jaszcz3, Krzysztof Narkiewicz6, Tomasz Grodzicki1, Andrzej Januszewicz2, Jerzy Gąsowski7.   

Abstract

BACKGROUND: Blood pressure (BP) control in the elderly is often limited by poor compliance with prescribed regimen. Both can be influenced by clinical cognitive or mood impairments; however, the impact of subclinical alterations of cognition or mood remains unknown.
OBJECTIVES: To assess the relation between cognition, mood, and BP control in treated older hypertensive patients.
DESIGN: Cross-sectional association study.
SETTING: Predefined substudy to the POLFOKUS nationwide survey investigating the correlates of poor BP control in patients randomly drawn from primary and specialist practices across Poland. PARTICIPANTS: 1988 outpatients ≥65 years of age treated for hypertension for at least 1 year. MEASUREMENTS: BP was mean of at least 2 office measurements. We assessed adherence to antihypertensive medications using a questionnaire and performed screening tests for cognitive deficits [Abbreviated Mental Test Score (AMTS)] and mood disorders [Geriatric Depression Scale (GDS)]. In all patients, we used a unified (BP <140/90 mm Hg) and in ≥80 years old a unified or age-specific (<150 mm Hg systolic BP) definition of BP control. We fitted logistic regression models to assess the probability of poor BP control in association with cognitive and mood disturbances.
RESULTS: The mean [standard deviation (SD)] age of 1988 (65.6% women) patients was 73.9 (6.0) years (19.3% ≥80 years old). Cognitive and mood impairments were observed in 8.0% and 37.2%, respectively. Mean systolic and diastolic BP were 141.8 (16.4) and 83.6 (9.5) mm Hg, respectively. According to age-stratified and unified definition of proper BP control, goal BP was achieved in 65.4% and 38.5% patients ≥80 years of age, respectively. In younger patients, the control reached 46%. Globally, 66% patients adhered to antihypertensive medications. Poor compliance was related to cognitive and mood impairments. When unified goal was applied, there was a 15.0% higher risk of finding poor BP control per 1 score lost in AMTS and an 8.0% increase per 1 score gained in GDS (all P < .001).
CONCLUSION: Poorer BP control is related to subclinical worsening of cognition and mood, which supports widespread use of the Comprehensive Geriatric Assessment even in apparently self-dependent older patients with hypertension.
Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BP control; Cognitive impairment; elderly; mood disturbances; subclinical; survey

Mesh:

Year:  2016        PMID: 27502451     DOI: 10.1016/j.jamda.2016.06.021

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  3 in total

1.  The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.

Authors:  Michael Ouk; Che-Yuan Wu; Jennifer S Rabin; Aaron Jackson; Jodi D Edwards; Joel Ramirez; Mario Masellis; Richard H Swartz; Nathan Herrmann; Krista L Lanctôt; Sandra E Black; Walter Swardfager
Journal:  Alzheimers Res Ther       Date:  2021-02-11       Impact factor: 6.982

2.  Factors associated with intensification of antihypertensive drug therapy in patients with poorly controlled hypertension.

Authors:  Olga Siga; Barbara Wizner; Barbara Gryglewska; Jolanta Walczewska; Tomasz Grodzicki
Journal:  J Geriatr Cardiol       Date:  2019-01       Impact factor: 3.327

3.  Negative emotions in community-dwelling adults with prediabetes and hypertension.

Authors:  Qianling Zhuang; Lirong Wu; Wang Ting; Lin Jie; Jingying Zou; Jiangang Du
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.